
Human GTPase KRas 5-13, KLVVVGACGV
Description
About Human GTPase KRas 5-13, KLVVVGACGV
The Human GTPase KRas (mutated sequence of KLVVVGAGG) Peptide (IEDB: 1087578) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The GTPase KRas Peptide, H-KLVVVGACGV-OH (Uniprot: P01116 aa: 5-13) from JPT is produced under strict quality control and quality management.
Human GTPase KRas 5-13, KLVVVGACGV - Specifications
- Peptide sequence: H-KLVVVGACGV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Lung cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human GTPase KRas 5-13, KLVVVGACGV
References:
Read References with JPT’s Antigen Peptides
Human GTPase KRas 5-13, KLVVVGACGV has been described in:
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment., J Immunother Cancer, 2019 (PMID: 31511069)
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations., J Immunother Cancer, 2021 (PMID: 34244308)
Documentation
Documentation for Human GTPase KRas 5-13, KLVVVGACGV
Properties
Properties of Human GTPase KRas 5-13, KLVVVGACGV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Lung cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | GTPase KRas |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human GTPase KRas 5-13, KLVVVGACGV
Information | Values |
---|---|
Sequence: | H-KLVVVGACGV-OH |
WT Sequence: | KLVVVGAGG |
Specifications: | 10mer peptide as TFA salt |